Ionis Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 77
What's happening
Earlier this month
-
Roche terminated Ionis's Huntington's drug program, leading to market scrutiny and investment decisions for all involved pharmaceutical companies.Some support1 report
-
GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Well supported12 reports
-
Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.Some support2 reports1 development inside
-
Ionis Pharmaceuticals is successfully treating Alexander disease using its drug Zanvastro.Some support2 reports
One to three months ago
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.Some support2 reports
-
Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.Some support1 report
-
Clinical failure of a product linked to Ionis Pharmaceuticals shifts financial focus onto Spinraza royalties.Some support2 reports
-
Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.Some support3 reports
-
The Ohio retirement system purchased stock in Ionis Pharmaceuticals, while Citigroup and Needham & Company issued related research notes.Some support1 report
-
Geode Capital Management lifted its position in Ionis Pharmaceuticals stock, which is listed on Nasdaq and filed with the SEC.Some support1 report
-
Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Some support1 report
-
Director Michael R. Hayden purchased stock in Ionis Pharmaceuticals as an insider investment.Some support1 report
Gone quiet
No new reports in 90+ days-
A late-stage trial failure involving a partner of AstraZeneca was announced, while the FDA concurrently approved Tryngolza for severe hypertriglyceridemia.Some support3 reports
-
Morgan Stanley raised its price objective for Ionis Pharmaceuticals stock, which trades on the Nasdaq exchange.Some support1 report
-
Ionis Pharmaceuticals listed on Nasdaq, partnered with AstraZeneca on a trial, and was investigated for potential securities law violations.Some support2 reports
-
Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.Well supported4 reports
-
Ionis Pharmaceuticals has been invited to participate in new Medicaid arrangements, coinciding with Donald Trump's promise of globally cheapest drug prices.Some support1 report
-
Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.Some support1 report
-
MarketBeat reported average ratings and TD Cowen reaffirmed a buy rating for Ionis Pharmaceuticals.Some support1 report
-
Ionis Pharmaceuticals was listed on the NASDAQ stock exchange and required to file transactions with the SEC on June 6, 2026.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Ionis Pharmaceuticals this week
News at the entities that move Ionis Pharmaceuticals most-
AstraZeneca TransactionalAstraZeneca plans a $2B facility in Tuas, Singapore, while President Shanmugaratnam conducts a state visit to Sweden.Moves Ionis Pharmaceuticals
-
SEC StructuralMarketBeat monitored consensus ratings for Sasol, and insider transactions related to the company were disclosed to the SEC on May 27, 2026.Moves Ionis Pharmaceuticals
-
Food and Drug Administration StructuralFDA conducted a search operation in Pune on January 1, 2026.Moves Ionis Pharmaceuticals
-
FDA StructuralFDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.Moves Ionis Pharmaceuticals
-
Novartis StructuralSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Ionis Pharmaceuticals
-
Hoffmann-La Roche TransactionalHoffmann-La Roche and Danaher are partnering with Nvidia to develop AI-driven labs for R&D and advance autonomous science.Moves Ionis Pharmaceuticals
Connections
The 39 strongest of 77, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Novartis holds global rights from Ionis for the joint development and commercialization of advanced experimental drugs.
-
AstraZeneca Transactional
The companies formed a joint development partnership for the Wainua gene-silencing drug candidate, which ultimately failed in late-stage clinical trials.
-
SEC Structural
Ionis Pharmaceuticals is subject to mandatory regulatory filings and disclosure requirements enforced by the SEC.
-
Securities and Exchange Commission Structural
Ionis Pharmaceuticals operates under the formal oversight and disclosure requirements of the Securities and Exchange Commission.
-
GSK Operational
GSK and Ionis Pharmaceuticals are actively co-developing the experimental drug bepirovirsen for the treatment of Hepatitis B.
-
Frank Bennett Structural
Frank Bennett serves as the Executive Vice President of Ionis Pharmaceuticals.
-
Nasdaq Structural
Ionis Pharmaceuticals is formally listed and trades on the Nasdaq stock exchange.
-
Recordati Transactional
Ionis licensed Zilganersen to Recordati.
Show all 39 connections
-
FDA Structural
The FDA functions as the critical regulatory gatekeeper, reviewing and approving products essential for Ionis Pharmaceuticals' market access.
-
Michael R. Hayden Structural
A director of Ionis Pharmaceuticals (A) is Michael R. Hayden (B), who is actively involved through insider stock purchases.
-
Food and Drug Administration Structural
The FDA formally approved Ionis Pharmaceuticals' drug Tryngolza for severe hypertriglyceridemia.
-
Alnylam Pharmaceuticals Operational
Alnylam and Ionis are currently partnered for clinical trials while also operating in a competitive market environment.
-
Alexander Transactional
Ionis Pharmaceuticals is actively seeking FDA approval for a treatment targeting the disease named after Alexander.
-
Citigroup Transactional
Citigroup made a market assessment leading to a reduction in its price objective for Ionis Pharmaceuticals.
-
Chris Hart Transactional
Chris Hart was employed by Ionis Pharmaceuticals for seven years.
-
Hoffmann-La Roche Transactional
Roche terminated the drug development partnership it held with Ionis Pharmaceuticals.
-
Needham & Company Mentioned together
Needham & Company published market research and analysis on Ionis Pharmaceuticals.
-
Arrowhead Pharmaceuticals Operational
The companies are active rivals competing for market efficacy in the hypertriglyceridemia therapeutic area.
-
Brown Brothers Harriman & Co. Structural
Brown Brothers Harriman acquired an investment stake in Ionis Pharmaceuticals, establishing an ownership relationship.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis and price targets for Ionis Pharmaceuticals stock.
-
Ark Invest Transactional
Ark Invest purchased shares of Ionis Pharmaceuticals despite recent clinical trial setbacks.
-
Needham Transactional
Needham downgraded its price targets for Ionis Pharmaceuticals in a current analyst report.
-
Biogen Operational
Ionis Pharmaceuticals and Biogen maintain an active operational partnership for drug development and clinical trials.
-
Benzinga Mentioned together
Benzinga tracks Ionis Pharmaceuticals' clinical trial outcomes and market performance.
-
Nvidia Operational
Analysts compare Ionis's potential against early investment theses in Nvidia's operational space.
-
MarketBeat Mentioned together
MarketBeat provides financial data and analyst coverage for Ionis Pharmaceuticals.
-
Raymond James Financial Mentioned together
Raymond James Financial issued a price objective report on Ionis Pharmaceuticals.
-
Company Transactional
The relationship is currently under investigation for potential securities law violations.
-
Geode Capital Management Transactional
Geode Capital Management lifted its investment position in Ionis Pharmaceuticals stock.
-
TTR Structural
Ionis Pharmaceuticals is focused on developing therapeutic agents that specifically target the TTR protein.
-
Bank of America Mentioned together
Bank of America boosted its target price on Ionis Pharmaceuticals.
-
New York Shared context
The company operates within the market infrastructure located in New York.
-
Medicare Structural
Ionis Pharmaceuticals interacts with Medicare through pilot arrangements, testing market access limits.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided market coverage on Ionis Pharmaceuticals, specifically decreasing its price target.
-
American Heart Association Mentioned together
Ionis Pharmaceuticals presented its clinical trial results at an American Heart Association scientific session.
-
Donald Trump Mentioned together
Evidence suggests Ionis Pharmaceuticals was mentioned in connection with Donald Trump's ventures, but the nature of the connection is undefined.
-
TD Cowen Mentioned together
TD Cowen provided investment research coverage for Ionis Pharmaceuticals, including reaffirming a buy rating.
-
AstraZeneca Structural
Ionis Pharmaceuticals and AstraZeneca are formal partners in drug development, as evidenced by AstraZeneca's trial failure impacting the collaboration.
-
Ohio Transactional
Ohio's retirement system purchased stock in Ionis Pharmaceuticals.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
8 events- Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
- Ionis Pharmaceuticals is successfully treating Alexander disease using its drug Zanvastro.
- Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Clinical failure of a product linked to Ionis Pharmaceuticals shifts financial focus onto Spinraza royalties.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- The Ohio retirement system purchased stock in Ionis Pharmaceuticals, while Citigroup and Needham & Company issued related research notes.
- Geode Capital Management lifted its position in Ionis Pharmaceuticals stock, which is listed on Nasdaq and filed with the SEC.
August 2026
2 eventsShow 2 earlier months
July 2026
4 events- A late-stage trial failure involving a partner of AstraZeneca was announced, while the FDA concurrently approved Tryngolza for severe hypertriglyceridemia.
- Morgan Stanley raised its price objective for Ionis Pharmaceuticals stock, which trades on the Nasdaq exchange.
- Ionis Pharmaceuticals listed on Nasdaq, partnered with AstraZeneca on a trial, and was investigated for potential securities law violations.
- Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.
June 2026
6 events- GSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Ionis Pharmaceuticals has been invited to participate in new Medicaid arrangements, coinciding with Donald Trump's promise of globally cheapest drug prices.
- Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.
- MarketBeat reported average ratings and TD Cowen reaffirmed a buy rating for Ionis Pharmaceuticals.
- Ionis Pharmaceuticals was listed on the NASDAQ stock exchange and required to file transactions with the SEC on June 6, 2026.